{
  "slug": "cannabis-use-disorder",
  "question": "What are the odds of developing cannabis use disorder?",
  "category": "health",
  "tags": [
    "substance-use",
    "mental-health"
  ],
  "no_reliable_estimate": false,
  "perceived": {
    "description": "Cannabis occupies an unusual position in public risk perception: it is widely regarded as the drug least likely to cause dependence, often in explicit contrast to alcohol, opioids, or stimulants. The political framing of legalization debates has reinforced this view — advocates have emphasized relative safety compared to alcohol, and the term \"marijuana use disorder\" does not have the cultural salience of \"alcoholism\" or \"opioid addiction.\" Many users and non-users alike believe cannabis is simply not addictive in any meaningful sense. That belief is incorrect for a substantial minority of users. The post-2018 legalization wave has also made high-potency products — concentrates, edibles, and vapes with THC concentrations far above what was available in prior decades — the norm in legal markets, changing the pharmacological exposure profile in ways that older survey data may not fully capture.\n",
    "rough_estimate": "~1-2% of adults",
    "kind": "intuition"
  },
  "native": {
    "display": "6.3% of US adults meet DSM-5 criteria for cannabis use disorder at some point in their lifetime (NESARC-III, 2012–2013)",
    "numerator": 6.3,
    "denominator": 100,
    "unit": "share of US adults with lifetime DSM-5 cannabis use disorder diagnosis",
    "population": "US adults aged 18 and older (NESARC-III, N=36,309, face-to-face interviews 2012–2013)"
  },
  "normalized": {
    "lifetime_us_adult": 0.063,
    "display": "~1 in 16 US adults develops cannabis use disorder at some point in their lifetime",
    "log_value": -1.2,
    "assumptions": "Hasin et al. (American Journal of Psychiatry, 2016) used the NESARC-III data (N=36,309 US adults, 2012–2013) with DSM-5 diagnostic criteria to estimate lifetime cannabis use disorder prevalence at 6.3% and 12-month prevalence at 2.5%. The lifetime figure is used directly as the normalized estimate: it already represents the US adult population and encompasses the full adult lifespan captured by retrospective structured interviews. Among adults who have ever used cannabis, the conditional probability of developing CUD is substantially higher. The Lopez-Quintero et al. (2011, Drug and Alcohol Dependence) analysis of NESARC-I data found that approximately 8.9% of ever-users transition to cannabis dependence — the per-user conditional rate. The NESARC-III all-adult 6.3% figure is used here because the question asks about population-level lifetime risk for a US adult, not conditional risk given use. SAMHSA 2024 NSDUH found 20.6 million past-year CUD among US residents 12+, consistent with the high end of prevalence estimates once cannabis use rates are applied.\n",
    "uncertainty": {
      "low": 0.04,
      "high": 0.09
    },
    "scope": "us_adult_lifetime"
  },
  "sources": [
    {
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC5026387/",
      "title": "Prevalence and Correlates of DSM-5 Cannabis Use Disorder, 2012–2013: Findings from the National Epidemiologic Survey on Alcohol and Related Conditions–III",
      "publisher": "Hasin DS et al. — American Journal of Psychiatry, 2016",
      "source_type": "peer_reviewed",
      "statistic": "Lifetime and 12-month prevalences of DSM-5 cannabis use disorder among US adults were 6.3% and 2.5%, respectively (NESARC-III, N=36,309)",
      "excerpt": "\"The prevalences of 12-month and lifetime cannabis use disorder were 2.5% and 6.3%. Odds of 12-month and lifetime cannabis use disorder were higher for men, Native Americans, unmarried individuals, those with low incomes, and young adults; cannabis use disorder was associated with other substance use disorders, affective disorders, anxiety, and personality disorders.\"\n",
      "source_date": "2016-03-01",
      "source_accessed": "2026-05-04",
      "archive_url": "http://web.archive.org/web/20260505050556/https://pmc.ncbi.nlm.nih.gov/articles/PMC5026387/",
      "calculation_notes": "The 6.3% lifetime prevalence is used directly as the native numerator (6.3 per 100 US adults). This is the primary calculation input, representing the first nationally representative DSM-5 CUD prevalence estimate using structured diagnostic interviews. The 2.5% 12-month figure confirms the disorder is active for many adults at any given time, not merely historical.\n",
      "independence_note": "NESARC-III was conducted by NIAAA using probability sampling and structured clinical interviews (AUDADIS-5), methodologically distinct from SAMHSA NSDUH self-report instruments.\n"
    },
    {
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC5037576/",
      "title": "Prevalence of Marijuana Use Disorders in the United States Between 2001-2002 and 2012-2013",
      "publisher": "Hasin DS et al. — JAMA Psychiatry, 2015",
      "source_type": "peer_reviewed",
      "statistic": "Past-year prevalence of DSM-IV marijuana use disorder increased from 1.5% in 2001-2002 to 2.9% in 2012-2013; marijuana use more than doubled over the same period",
      "excerpt": "\"The past-year prevalence of marijuana use was 4.1% in 2001-2002 and 9.5% in 2012-2013. The past-year prevalence of DSM-IV marijuana use disorder was 1.5% in 2001-2002 and 2.9% in 2012-2013 (P < .05). Significant increases were found across all demographic subgroups.\"\n",
      "source_date": "2015-12-01",
      "source_accessed": "2026-05-04",
      "archive_url": "http://web.archive.org/web/20260223205053/https://pmc.ncbi.nlm.nih.gov/articles/PMC5037576/",
      "calculation_notes": "This study uses DSM-IV criteria and past-year prevalence, so the absolute figures are lower than the DSM-5 lifetime estimates in Hasin et al. 2016. It is used here to establish the trend: both cannabis use and cannabis use disorder have increased substantially since 2001-2002, with disorder prevalence roughly doubling. The post-legalization era (2018 onward) is not captured in either NESARC study and likely represents a further increase in exposure and conditional disorder rates.\n",
      "independence_note": "Both Hasin 2015 (JAMA Psychiatry) and Hasin 2016 (Am J Psychiatry) draw on NESARC wave data. They are not fully independent sources but use different diagnostic criteria (DSM-IV vs DSM-5) and different comparison years, providing genuine methodological triangulation on the trend.\n"
    },
    {
      "url": "https://www.samhsa.gov/data/sites/default/files/reports/rpt56287/2024-nsduh-annual-national-report.pdf",
      "title": "Key Substance Use and Mental Health Indicators in the United States: Results from the 2024 National Survey on Drug Use and Health",
      "publisher": "Substance Abuse and Mental Health Services Administration (SAMHSA)",
      "source_type": "govt_report",
      "statistic": "20.6 million people aged 12 or older had past-year cannabis use disorder in 2024, making it the most common drug use disorder in the US",
      "excerpt": "\"Marijuana use disorder was the most common drug use disorder (20.6 million), followed by opioid use disorder (4.8 million) and central nervous system stimulant use disorder (4.3 million). In 2024, 44.3 million individuals reported marijuana use in the past month.\"\n",
      "source_date": "2025-07-14",
      "source_accessed": "2026-05-04",
      "archive_url": "http://web.archive.org/web/20260512142703/https://www.samhsa.gov/data/sites/default/files/reports/rpt56287/2024-nsduh-annual-national-report.pdf",
      "calculation_notes": "SAMHSA 2024 NSDUH: 20.6M past-year CUD / ~260M US adults ≈ 7.9% past-year CUD prevalence. This figure is notably higher than the NESARC-III 2.5% 12-month estimate, reflecting both the increase in cannabis use since 2012-2013 and instrument differences between NSDUH and NESARC. It is used here as a cross-validation anchor showing that post-legalization cannabis use disorder rates are higher than the NESARC-III figures, supporting the upper end of the uncertainty range. The 6.3% lifetime estimate from 2012-2013 is almost certainly an undercount for today's adult cohort.\n"
    }
  ],
  "comparison_anchors": [
    {
      "label": "Alcohol use disorder (lifetime, US adult)",
      "lifetime_us_adult": 0.291
    },
    {
      "label": "Opioid addiction after surgical prescription (lifetime, US adult)",
      "lifetime_us_adult": 0.0088
    },
    {
      "label": "Gambling disorder causing financial ruin (lifetime, US adult)",
      "lifetime_us_adult": 0.0063
    }
  ],
  "personal_factor_multipliers": [
    {
      "factor": "daily or near-daily cannabis user",
      "multiplier": 5,
      "notes": "Frequency of use is the dominant behavioral predictor; daily users have substantially higher conditional CUD rates"
    },
    {
      "factor": "use began in adolescence (before age 18)",
      "multiplier": 3,
      "notes": "Early onset of use is a robust predictor of CUD; the developing adolescent brain is more vulnerable to dependence"
    },
    {
      "factor": "male",
      "multiplier": 1.5,
      "notes": "Men have higher CUD rates than women in NESARC-III, consistent with higher rates of heavy use"
    },
    {
      "factor": "co-occurring anxiety or mood disorder",
      "multiplier": 2.5,
      "notes": "NESARC-III found strong comorbidity; cannabis is commonly used for self-medication of anxiety and insomnia"
    },
    {
      "factor": "uses only occasionally (monthly or less)",
      "multiplier": 0.15,
      "notes": "CUD is strongly use-pattern-dependent; occasional users face much lower conditional risk"
    }
  ],
  "short_label": "Cannabis use disorder",
  "myth_framing": "underrated",
  "outcome_severity": "serious_harm",
  "exposure_pattern": "cumulative",
  "outcome_type": "mental_trauma",
  "valence": "negative",
  "caveats": "The 6.3% lifetime prevalence is drawn from 2012-2013 NESARC-III data, before legalization in most US states. Since 2018, both cannabis use prevalence and use disorder rates have increased substantially; SAMHSA 2024 found 20.6 million past-year CUD cases, suggesting the lifetime prevalence for today's younger cohort will be higher than 6.3% by the time they reach the age of the NESARC-III respondents. The conditional risk among ever-users is substantially higher than the all-adult 6.3% — approximately 8.9% of ever-users develop dependence, per Lopez-Quintero et al. (2011, Drug and Alcohol Dependence, NESARC-I data). Post-legalization products — concentrates, vapes, and edibles with THC concentrations of 40-90% versus the 5-10% of typical cannabis sold in 2000 — represent a meaningfully different pharmacological exposure than the products used by most NESARC-III respondents. The 6.3% figure should be treated as a lower bound for current and future adult cohorts. DSM-5 CUD requires at least 2 of 11 criteria; tolerance and withdrawal are included but not required, meaning the disorder captures a wider range of problematic use patterns than colloquial \"addiction.\"\n",
  "quality_score": {
    "d1": 5,
    "d2": 5,
    "d3": 5,
    "d4": 4,
    "d5": 5,
    "d6": 5,
    "d7": 4,
    "d8": 5,
    "avg": 4.75,
    "scored_by": "claude-code-8d",
    "scored_at": "2026-05-25",
    "methodology_version": "1.2"
  },
  "reviewer": "8d-eval-2026-05-16",
  "last_reviewed": "2026-05-16",
  "reviewed": true,
  "generated_at": "2026-05-04",
  "image": {
    "alt": "A small calendar showing months accumulating beside a single leaf silhouette, flat vector illustration in muted green and grey tones."
  },
  "attribution": "Likelier — https://likelier.app",
  "license": "https://creativecommons.org/licenses/by-sa/4.0/",
  "support": "https://buymeacoffee.com/kgluszczyk?via=likelier&utm_content=api-fear-single",
  "canonical_url": "https://likelier.app/cannabis-use-disorder"
}